MRKR Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	13 126.00
Gjennomsnittsvolum	18 037.00
Markedsverdi	37.57M
EPS	$0 ( 2024-03-27 )
Neste inntjeningsdato	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.65
ATR14	$0.101 (2.39%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-30	Lurier Eliot M	Buy	0
2021-03-16	Eansor Norman David	Buy	14 285	Common Stock
2023-06-06	Eansor Norman David	Buy	8 000	Stock Option (right to buy)
2021-03-25	Eansor Norman David	Buy	7 142	Common Stock
2021-03-25	Eansor Norman David	Sell	14 285	Common Stock

INSIDER POWER
100.00
Last 91 transactions
Buy: 66 397 235 \| Sell: 1 245 536

Marker Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Marker Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$3.31M
Bruttogevinst:	$-7.11M (-214.60 %)
EPS:	$-1.930

FY	2023
Omsetning:	$3.31M
Bruttogevinst:	$-7.11M (-214.60 %)
EPS:	$-1.930

FY	2022
Omsetning:	$9.00M
Bruttogevinst:	$5.32M (59.13 %)
EPS:	$-3.58

FY	2021
Omsetning:	$1 242.00
Bruttogevinst:	$1 241.71 (100.00 %)
EPS:	$-8.90

Financial Reports:

No articles found.

Marker Therapeutics Inc

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.